RxDoctor Payments DataLook up a doctor →

Caroline Rivera Olomo, MD

Hematology & Oncology · Barceloneta, PRNPI 1033305123

Payments from drug & device makers

$29,753in general payments, 2019–2025

Across 1,225 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4K
  • AstraZeneca$4K
  • E.r. Squibb & Sons, L.L.C.$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • PBG Puerto Rico LLC$2K
  • plus $14K from 51 others

What the payments were for

  • Consulting fees$2,8259%
  • Food & beverage$26,09888%
  • Education$8303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,753 in reported general payments places this provider in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$43,153
Medicare patients
25
Services billed
3,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib74$1,151,119
RevlimidLenalidomide30$504,264
LenvimaLenvatinib Mesylate17$417,593
NerlynxNeratinib Maleate11$169,664
ErleadaApalutamide11$162,398
NinlaroIxazomib Citrate12$157,524
GilotrifAfatinib Dimaleate11$127,075
FulphilaPegfilgrastim-Jmdb56$122,040
ProliaDenosumab64$113,944
ArimidexAnastrozole52$92,172
Abiraterone Acetate17$21,986
EliquisApixaban32$21,733
RetacritEpoetin Alfa-Epbx12$20,877
Anastrozole1,372$19,974
XareltoRivaroxaban17$9,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$388$1,151,11974 claims
Bristol Myers SquibbRevlimid$213$504,26430 claims
Eisai Inc.Lenvima$915$417,59317 claims
Johnson & JohnsonErleada, Xarelto$1,685$172,21228 claims
Puma Biotechnology, Inc.Nerlynx$472$169,66411 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$24$157,52412 claims
AmgenProlia$993$113,94464 claims
PfizerEliquis, Retacrit$889$42,61044 claims
AbbVieSynthroid$1,915$83215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Barceloneta

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →